Skip to main content
Erschienen in: Clinical Rheumatology 1/2012

01.01.2012 | Original Article

Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren’s syndrome

verfasst von: Tetsutaro Kitagawa, Koichi Shibasaki, Shuji Toya

Erschienen in: Clinical Rheumatology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Anti-SS-A/Ro antibody (SS-A) and anti-SS-B/La antibody (SS-B) are important serologic markers in the diagnostic criteria for Primary Sjögren’s syndrome (SS). Although anti-centromere antibody (ACA)-positive SS is frequently experienced, ACA is not included in these criteria. The purpose of this study was to identify the clinical features of ACA-positive SS and discuss the usefulness of ACA in diagnosing SS. Forty-five patients with SS were divided into the following three groups: SS-A only-positive group (n = 17), SS-A and SS-B both-positive group (n = 18), and ACA only-positive group (n = 10). As a control, 54 patients without SS who were negative for antinuclear antibodies were also evaluated. The following items were compared among groups: Saxon’s test, unstimulated whole salivary flow (UWSF), salivary gland scintigraphy (SGS), histopathologic examination of the minor salivary glands, Schirmer’s test, and fluorescein staining of the cornea. In the ACA only-positive group, Saxon’s test was 0.21 ± 0.26 g/2 min (mean ± SD) and UWSF was 0.16 ± 0.25 ml/10 min (mean ± SD), showing a significant decrease in salivary secretion (p < 0.05; vs. non-SS). On SGS, accumulation and disappearance of 99mTcO 4 were significantly decreased (p < 0.05; vs. non-SS). Histopathologic examination showed moderate or severe lymphocytic infiltration and tissue destruction in all cases, similar to that in the SS-A- and/or SS-B-positive groups. Schirmer’s test and fluorescein staining were positive in 60% and 80%, respectively. Impaired lacrimal secretion and keratoconjunctivitis sicca were similar to those in SS-A- and/or SS-B-positive groups. These results suggest that ACA is an autoantibody reflecting impairment in the salivary and lacrimal glands and may be a useful serologic marker for SS.
Literatur
1.
Zurück zum Zitat Sjögren H (1933) Zur kenntnis der keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol (Copenhagen). Suppl II:1–151. Sjögren H (1933) Zur kenntnis der keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol (Copenhagen). Suppl II:1–151.
2.
Zurück zum Zitat Ramos-Casals M, Nardi N, Brito-Zerón P, Aguiló S, Gil V, Delgado G, Bové A, Font J (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35:312–321PubMedCrossRef Ramos-Casals M, Nardi N, Brito-Zerón P, Aguiló S, Gil V, Delgado G, Bové A, Font J (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35:312–321PubMedCrossRef
3.
Zurück zum Zitat Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631PubMedCrossRef Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 77:1627–1631PubMedCrossRef
4.
Zurück zum Zitat Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625PubMedCrossRef Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625PubMedCrossRef
5.
Zurück zum Zitat Frizler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRef Frizler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRef
6.
Zurück zum Zitat Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (1984) The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 59:700–706PubMed Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (1984) The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 59:700–706PubMed
7.
Zurück zum Zitat Powell FC, Schroeter AL, Dickson ER (1987) Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med 62:75–82PubMed Powell FC, Schroeter AL, Dickson ER (1987) Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med 62:75–82PubMed
8.
Zurück zum Zitat Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32:297–301PubMedCrossRef Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32:297–301PubMedCrossRef
9.
Zurück zum Zitat Caramaschi P, Biasi D, Carletto A, Manzo T, Randon M, Zeminian S, Bambara LM (1997) Sjögren’s syndrome with anticentromere antibodies. Rev Rheum Engl Ed 64:785–788 Caramaschi P, Biasi D, Carletto A, Manzo T, Randon M, Zeminian S, Bambara LM (1997) Sjögren’s syndrome with anticentromere antibodies. Rev Rheum Engl Ed 64:785–788
10.
Zurück zum Zitat Hsu TC, Chang CH, Lin MC, Liu ST, Yen TJ, Tsay GJ (2006) Anti-CENP-H antibodies in patients with Sjogren’s syndrome. Rheumatol Int 26:298–303PubMedCrossRef Hsu TC, Chang CH, Lin MC, Liu ST, Yen TJ, Tsay GJ (2006) Anti-CENP-H antibodies in patients with Sjogren’s syndrome. Rheumatol Int 26:298–303PubMedCrossRef
11.
Zurück zum Zitat Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM (2010) Anticentromere antibody positive Sjögren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther 12:R47PubMedCrossRef Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM (2010) Anticentromere antibody positive Sjögren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther 12:R47PubMedCrossRef
12.
Zurück zum Zitat Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y (2005) Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 32:1488–1494PubMed Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y (2005) Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 32:1488–1494PubMed
13.
Zurück zum Zitat Katano K, Kawano M, Koni I, Sugai S, Muro Y (2001) Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol 28:2238–2244PubMed Katano K, Kawano M, Koni I, Sugai S, Muro Y (2001) Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol 28:2238–2244PubMed
14.
Zurück zum Zitat Takada K, Suzuki K, Okada M, Nakashima M, Ohsuzu F (2006) Salivary production rates fall with age in subjects having anticentromere, anti-Ro, and/or anti-La antibodies. Scand J Rheumatol 35:23–28PubMedCrossRef Takada K, Suzuki K, Okada M, Nakashima M, Ohsuzu F (2006) Salivary production rates fall with age in subjects having anticentromere, anti-Ro, and/or anti-La antibodies. Scand J Rheumatol 35:23–28PubMedCrossRef
15.
Zurück zum Zitat Yan SM, Zeng XF, Zhao Y, Dong Y (2008) A clinical analysis of primary Sjögren’s syndrome with anticentromere antibodies. Zhonghua Nei ke Za Zhi 47:296–299PubMed Yan SM, Zeng XF, Zhao Y, Dong Y (2008) A clinical analysis of primary Sjögren’s syndrome with anticentromere antibodies. Zhonghua Nei ke Za Zhi 47:296–299PubMed
16.
Zurück zum Zitat Vitali C, Bombardieri S, Jonsson R, Moutsopolos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopolos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558PubMedCrossRef
17.
Zurück zum Zitat Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K (2004) Revised Japanese criteria for Sjogren’s syndrome (1999): availability and validity. Mod Rheumatol 14:425–434CrossRef Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K (2004) Revised Japanese criteria for Sjogren’s syndrome (1999): availability and validity. Mod Rheumatol 14:425–434CrossRef
18.
Zurück zum Zitat Toyama M, Tsuchimochi M (2004) Salivary gland scintigraphy in patients with Sjögren’s syndrome. Dental Radiol 44:53–58 Toyama M, Tsuchimochi M (2004) Salivary gland scintigraphy in patients with Sjögren’s syndrome. Dental Radiol 44:53–58
19.
Zurück zum Zitat Greenspan JS, Daniels TE, Talal N, Sylvester RA (1974) The histopathology of Sjögren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 37:217–229PubMedCrossRef Greenspan JS, Daniels TE, Talal N, Sylvester RA (1974) The histopathology of Sjögren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 37:217–229PubMedCrossRef
20.
Zurück zum Zitat Maeda N, Yamaji K, Kimura K, Kim Y, Tsuda H, Hirose S, Hashimoto H (2005) Analysis of clinical questionnaire of Tokyo Metropolitan Government for Sjogren’s syndrome. Jpn J Clin Immunol 28:398–406CrossRef Maeda N, Yamaji K, Kimura K, Kim Y, Tsuda H, Hirose S, Hashimoto H (2005) Analysis of clinical questionnaire of Tokyo Metropolitan Government for Sjogren’s syndrome. Jpn J Clin Immunol 28:398–406CrossRef
21.
Zurück zum Zitat Lundström IM, Lundström FD (1995) Subjective and clinical oral symptoms in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 13:725–731PubMed Lundström IM, Lundström FD (1995) Subjective and clinical oral symptoms in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 13:725–731PubMed
22.
Zurück zum Zitat Pedersen AM, Reibel J, Nauntofte B (1999) Primary Sjögren’s syndrome (pSS): subjective symptoms and salivary findings. J Oral Pathol Med 28:303–311PubMedCrossRef Pedersen AM, Reibel J, Nauntofte B (1999) Primary Sjögren’s syndrome (pSS): subjective symptoms and salivary findings. J Oral Pathol Med 28:303–311PubMedCrossRef
23.
Zurück zum Zitat Márton K, Boros I, Varga G, Zelles T, Fejérdy P, Zeher M, Nagy G (2006) Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjögren’s syndrome. Oral Dis 12:480–486PubMedCrossRef Márton K, Boros I, Varga G, Zelles T, Fejérdy P, Zeher M, Nagy G (2006) Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjögren’s syndrome. Oral Dis 12:480–486PubMedCrossRef
24.
Zurück zum Zitat Pedersen AM, Reibel J, Nordgarden H, Bergem HO, Jensen JL, Nauntofte B (1999) Primary Sjögren’s syndrome: salivary gland function and clinical oral findings. Oral Dis 5:128–138PubMedCrossRef Pedersen AM, Reibel J, Nordgarden H, Bergem HO, Jensen JL, Nauntofte B (1999) Primary Sjögren’s syndrome: salivary gland function and clinical oral findings. Oral Dis 5:128–138PubMedCrossRef
25.
Zurück zum Zitat Aung W, Murata Y, Ishida R, Takahashi Y, Okada N, Shibuya H (2001) Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjögren’s syndrome. J Nucl Med 42:38–43PubMed Aung W, Murata Y, Ishida R, Takahashi Y, Okada N, Shibuya H (2001) Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjögren’s syndrome. J Nucl Med 42:38–43PubMed
26.
Zurück zum Zitat Tsujii H, Furudate M, Irie G (1980) Effects of radiotherapy on the salivary gland as measured by 99mTcO 4 − . Nippon Igaku Hoshasen Gakkai Zasshi 40:485–493PubMed Tsujii H, Furudate M, Irie G (1980) Effects of radiotherapy on the salivary gland as measured by 99mTcO 4 . Nippon Igaku Hoshasen Gakkai Zasshi 40:485–493PubMed
27.
Zurück zum Zitat Adams BK, Al Attia HM, Parkar S (2003) Salivary gland scintigraphy in Sjögren’s syndrome: are quantitative indices the answer? Nucl Med Commun 24:1011–1016PubMedCrossRef Adams BK, Al Attia HM, Parkar S (2003) Salivary gland scintigraphy in Sjögren’s syndrome: are quantitative indices the answer? Nucl Med Commun 24:1011–1016PubMedCrossRef
28.
Zurück zum Zitat Hermann GA, Vivino FB, Shnier D, Krumm RP, Mayrin V, Shore JB (1998) Variability of quantitative scintigraphic salivary indices in normal subjects. J Nucl Med 39:1260–1263PubMed Hermann GA, Vivino FB, Shnier D, Krumm RP, Mayrin V, Shore JB (1998) Variability of quantitative scintigraphic salivary indices in normal subjects. J Nucl Med 39:1260–1263PubMed
29.
Zurück zum Zitat Aung W, Yamada I, Umehara I, Ohbyashi N, Yoshino N, Shibuya H (2000) Sjögren’s syndrome: comparison of assessments with quantitative salivary gland scintigraphy and contrast sialography. J Nucl Med 41:257–262PubMed Aung W, Yamada I, Umehara I, Ohbyashi N, Yoshino N, Shibuya H (2000) Sjögren’s syndrome: comparison of assessments with quantitative salivary gland scintigraphy and contrast sialography. J Nucl Med 41:257–262PubMed
30.
Zurück zum Zitat Kohn WG, Ship JA, Atkinson JC, Patton LL, Fox PC (1992) Salivary gland 99m-Tc-scintigraphy: a grading scale and correlation with major salivary gland flow rates. J Oral Pathol Med 21:70–74PubMedCrossRef Kohn WG, Ship JA, Atkinson JC, Patton LL, Fox PC (1992) Salivary gland 99m-Tc-scintigraphy: a grading scale and correlation with major salivary gland flow rates. J Oral Pathol Med 21:70–74PubMedCrossRef
31.
Zurück zum Zitat Shizukuishi K, Nagaoka S, Kinno Y, Saito M, Takahashi N, Kawamoto M, Abe A, Jin L, Inoue T (2003) Scoring analysis of salivary gland scintigraphy in patients with Sjögren’s syndrome. Ann Nucl Med 17:627–631PubMedCrossRef Shizukuishi K, Nagaoka S, Kinno Y, Saito M, Takahashi N, Kawamoto M, Abe A, Jin L, Inoue T (2003) Scoring analysis of salivary gland scintigraphy in patients with Sjögren’s syndrome. Ann Nucl Med 17:627–631PubMedCrossRef
32.
Zurück zum Zitat Mita S, Kohno M, Matsuoka Y, Matsuoka Y, lrimajiri S, Fujimori I, Fukuda J (1981) Diagnostic availability of RI-sialography in Sjogren’s syndrome. Ryumachi 21:305–316 Mita S, Kohno M, Matsuoka Y, Matsuoka Y, lrimajiri S, Fujimori I, Fukuda J (1981) Diagnostic availability of RI-sialography in Sjogren’s syndrome. Ryumachi 21:305–316
33.
Zurück zum Zitat Sugihara T, Yoshimura Y (1988) Scintigraphic evaluation of the salivary glands in patients with Sjögren’s syndrome. Int J Oral Maxillofac Surg 17:71–75PubMedCrossRef Sugihara T, Yoshimura Y (1988) Scintigraphic evaluation of the salivary glands in patients with Sjögren’s syndrome. Int J Oral Maxillofac Surg 17:71–75PubMedCrossRef
34.
Zurück zum Zitat Vinagre F, Santos MJ, Prata A, da Silva JC, Santos AI (2009) Assessment of salivary gland function in Sjögren’s syndrome: the role of salivary gland scintigraphy. Autoimmun Rev 8:672–676PubMedCrossRef Vinagre F, Santos MJ, Prata A, da Silva JC, Santos AI (2009) Assessment of salivary gland function in Sjögren’s syndrome: the role of salivary gland scintigraphy. Autoimmun Rev 8:672–676PubMedCrossRef
35.
Zurück zum Zitat Sawada S, Sugai S, Iijima S, Takei M, Paredes E, Hayama T, Nishinarita S, Hosokawa Y, Horie T, Obara T (1992) Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren’s syndrome. Am J Med 92:134–140PubMedCrossRef Sawada S, Sugai S, Iijima S, Takei M, Paredes E, Hayama T, Nishinarita S, Hosokawa Y, Horie T, Obara T (1992) Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren’s syndrome. Am J Med 92:134–140PubMedCrossRef
36.
Zurück zum Zitat Bernstein RM, Callender ME, Neuberger JM, Hughes GR, Williams R (1982) Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 41:612–614PubMedCrossRef Bernstein RM, Callender ME, Neuberger JM, Hughes GR, Williams R (1982) Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 41:612–614PubMedCrossRef
37.
Zurück zum Zitat Makinen D, Fritzler M, Davis P, Sherlock S (1983) Anticentromere antibody in primary biliary cirrhosis. Arthritis Rheum 26:914–917PubMedCrossRef Makinen D, Fritzler M, Davis P, Sherlock S (1983) Anticentromere antibody in primary biliary cirrhosis. Arthritis Rheum 26:914–917PubMedCrossRef
38.
Zurück zum Zitat Chan HL, Lee YS, Hong HS, Kuo TT (1994) Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 19:298–302PubMedCrossRef Chan HL, Lee YS, Hong HS, Kuo TT (1994) Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 19:298–302PubMedCrossRef
39.
Zurück zum Zitat Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K (2007) Primary biliary cirrhosis(PBC)-CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol 26:596–600PubMedCrossRef Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K (2007) Primary biliary cirrhosis(PBC)-CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol 26:596–600PubMedCrossRef
40.
Zurück zum Zitat Ford AL, Kurien BT, Harley JB, Scofield RH (1998) Anti-centromere autoantibody in a patient evolving from a lupus/Sjögren’s overlap to the CREST variant of scleroderma. J Rheumatol 25:1419–1424PubMed Ford AL, Kurien BT, Harley JB, Scofield RH (1998) Anti-centromere autoantibody in a patient evolving from a lupus/Sjögren’s overlap to the CREST variant of scleroderma. J Rheumatol 25:1419–1424PubMed
41.
Zurück zum Zitat Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, Rosen A, Casciola-Rosen L (2006) Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann Rheum Dis 65:1028–1032PubMedCrossRef Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, Rosen A, Casciola-Rosen L (2006) Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann Rheum Dis 65:1028–1032PubMedCrossRef
Metadaten
Titel
Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren’s syndrome
verfasst von
Tetsutaro Kitagawa
Koichi Shibasaki
Shuji Toya
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 1/2012
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1789-z

Weitere Artikel der Ausgabe 1/2012

Clinical Rheumatology 1/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.